AGENTIX Corp. (OTC Pink: AGTX) stock soared 27% on Wednesday after announcing it entered into a worldwide exclusive license agreement and technology transfer agreement with the National Health Research Institutes of Taiwan ROC. In-play is DBPR211, an innovative new chemical entity with pre-clinical evidence demonstrating efficacy as a treatment for Obesity, Type 2 Diabetes (T2D), and Non-Alcoholic Fatty Liver Disease (NAFLD). Investors obviously liked what they saw, sending shares in this thinly-traded company significantly higher.
The better news could be that AGTX gets a head-start in the development process. The peripherally restricted cannabinoid receptor 1 antagonist has successfully completed preliminary pre-clinical and in vivo testing requirements. Even better, its prospects as a treatment are strengthened from the drug not crossing the blood-brain barrier. That’s an important consideration going forward. So is its marketing potential.
AGTX will be targeting the estimated 34.2 million people with Type 2 diabetes in the USA alone. Treatment targets further extend to the 42.9% of the obese population and the estimated 24% of US adults with Non-Alcoholic Fatty Liver Disease. Combined, it puts a billion-dollar market opportunity into AGTX’s crosshairs. Individually, the market potential can be worth hundreds of millions.
Innovative Treatment In-Play
There are also options in how AGTX can maximize the drug’s potential, with AGTX expecting to tailor treatment solutions for different patients depending on patient specifics and the disease. In focus is the endocannabinoid system, which plays a physiologic role in modulating energy balance, feeding behavior, lipoprotein metabolism, insulin sensitivity, and glucose homeostasis, which can contribute to cardiometabolic risk when dysregulated. If AGTX can regulate the functions, it may have a billion-dollar franchise. And with evidence already suggesting that the ECS is overactive in human obesity, AGTX may get a running start in developing its treatment candidate.
The terms are excellent. Under the license agreement, AGTX receives exclusive worldwide rights under several NHRI patents and patent applications to develop, manufacture, and sell DBPR211 to treat human diseases. Additional terms call for NHRI to assist with transferring and advancing the lead therapeutic candidates into GMP manufacturing ahead of AGTX’s planned Phase I clinical trial. That trial is expected to commence within the next 12 months. Trading ahead of the news, and the milestones that come with it, could be a wise consideration.
Rudy Mazzocchi, Chairman of the Board and Chief Executive Officer of AGENTIX, certainly thinks so. He said, “We are pleased to have such an outstanding partner as NHRI and look forward to working with them as we advance these therapies into the clinic. This is an important, valuable and strategic asset as we continue to expand and advance the development, clinical and commercial platform of the company.”
Dr. Jang-Yang Chang, Director of Institute of Biotechnology and Pharmaceutical Research at NHRI is optimistic as well, saying, “The opportunity to pair this promising therapeutic candidate with a strong commercial partner is an exciting collaboration for us.” He added, “We will continue to support the team at AGENTIX as they move this therapy into clinical trials.”
AGENTIX Could Emerge In 2H 2021-22
Indeed, AGENTIX is an under-the-radar company that is thinly traded on the OTC Pink markets. However, when the shares do catch a bid, they tend to rally hard. The stock is higher by more than 78% YTD. Thus, this vertically integrated company focused on developing and commercializing novel, science-driven biopharmaceuticals could be an attractive play for those investors that embrace both short and long-term investment opportunities.
And with its new license providing exclusivity to develop a promising asset that targets several significant drug market opportunities, additional news before the end of the year could fuel its YTD rally further.
Thus, its 78% gain could be a prelude to better things to come.
Disclaimers: Hawk Point Media Group, LLC. (Hawk Point Media) is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security.Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement. Hawk Point Media has not been, nor does it intend to be, compensated for the production and distribution of this content.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.